Baiyong Li
ORCID：0009-0002-2426-9656
发表论文 130 篇 · 总被引 3389 次 · h-index 31
代表论文
- Ivonescimab Plus Chemotherapy in Non–Small Cell Lung Cancer With EGFR Variant (2024 · JAMA · 被引 198)
- Cadonilimab plus platinum-based chemotherapy with or without bevacizumab as first-line treatment for persistent, recurrent, or metastatic cervical cancer (COMPASSION-16): a randomised, double-blind, placebo-controlled phase 3 trial in China (2024 · The Lancet · 被引 119)
- First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trial (2025 · Nature Medicine · 被引 95)
- Phase 1a dose escalation study of ivonescimab (AK112/SMT112), an anti-PD-1/VEGF-A bispecific antibody, in patients with advanced solid tumors (2024 · Journal for ImmunoTherapy of Cancer · 被引 77)
- Cadonilimab Combined with Chemotherapy with or without Bevacizumab as First-Line Treatment in Recurrent or Metastatic Cervical Cancer (COMPASSION-13): A Phase 2 Study (2024 · Clinical Cancer Research · 被引 62)
- Cadonilimab with chemotherapy in HER2-negative gastric or gastroesophageal junction adenocarcinoma: the phase 1b/2 COMPASSION-04 trial (2024 · Nature Medicine · 被引 49)